Related Experiment Video
Updated: Nov 13, 2025

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
Glioma Stem Cells as Immunotherapeutic Targets: Advancements and Challenges
Keenan Piper1,2, Lisa DePledge1,3, Michael Karsy4
1Ben & Catherine Ivy Center for Advanced Brain Tumor Treatment, Swedish Neuroscience Institute, Seattle, WA, United States.
Abstract:
Glioblastoma is the most common and lethal primary brain malignancy. Despite major investments in research into glioblastoma biology and drug development, treatment remains limited and survival has not substantially improved beyond 1-2 years. Cancer stem cells (CSC) or glioma stem cells (GSC) refer to a population of tumor originating cells capable of self-renewal and differentiation. While controversial and challenging to study, evidence suggests that GCSs may result in glioblastoma tumor recurrence and resistance to treatment. Multiple treatment strategies have been suggested at targeting GCSs, including immunotherapy, posttranscriptional regulation, modulation of the tumor microenvironment, and epigenetic modulation. In this review, we discuss recent advances in glioblastoma treatment specifically focused on targeting of GCSs as well as their potential integration into current clinical pathways and trials.
Insights
Glioblastoma treatment remains limited, but targeting glioma stem cells (GSCs) shows promise for overcoming recurrence and resistance. This review explores GSC-focused strategies for improved glioblastoma patient outcomes.
Area of Science:
- Neuro-oncology
- Cancer Biology
- Translational Medicine
Background:
- Glioblastoma is an aggressive primary brain tumor with poor prognosis.
- Current treatments offer limited survival benefits, often exceeding 1-2 years.
- Glioma stem cells (GSCs) are implicated in glioblastoma recurrence and treatment resistance.
Purpose of the Study:
- To review recent advances in glioblastoma treatment strategies targeting GSCs.
- To discuss the potential integration of GSC-targeting therapies into clinical practice.
- To highlight novel approaches for overcoming glioblastoma resistance.
Main Methods:
- Literature review of recent research on glioblastoma and GSCs.
- Analysis of therapeutic strategies targeting GSCs.
- Discussion of potential clinical applications and trial integration.
Main Results:
- GSCs are key drivers of glioblastoma recurrence and therapeutic resistance.
- Multiple strategies are emerging to target GSCs, including immunotherapy and epigenetic modulation.
- Targeting GSCs offers a promising avenue for improving glioblastoma treatment efficacy.
Conclusions:
- Targeting glioma stem cells represents a critical frontier in glioblastoma research.
- Integrating GSC-specific therapies into clinical trials may enhance patient survival.
- Further research is needed to fully elucidate and exploit GSC vulnerabilities in glioblastoma.
Related Concept Videos
Tumor Immunotherapy
Induced Pluripotent Stem Cells
Somatic...
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...

